Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hangzhou Cancer Hospital | OTHER |
| First People's Hospital of Yuhang District | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The primary objective of the study was to assess the appropriateness of antiviral therapy with nirmatrelvir-ritonavir in hospitalized patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Nirmatrelvir-Ritonavir | Hospitalized patients receiving at least one dose Nirmatrelvir-Ritonavir |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nirmatrelvir-Ritonavir | Drug | Nirmatrelvir-Ritonavir |
|
| Measure | Description | Time Frame |
|---|---|---|
| The prevalence of inappropriate use of nirmatrelvir-ritonavir | Four aspects were evaluated to identify the rationality of prescribing NMVr, including indication, administration (dose, timing, and duration), contraindications, and drug-drug interactions. | baseline |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
hospitalized patients receiving at least one dose nirmatrelvir-ritonavir
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Changcheng Shi | Contact | 86-13967157030 | cpushicc@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Changcheng Shi | First People's Hospital of Hangzhou | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Changcheng Shi | Recruiting | Hangzhou | Zhejiang | 310006 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35305258 | Background | Lamb YN. Nirmatrelvir Plus Ritonavir: First Approval. Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5. | |
| 36423149 | Background | Akinosoglou K, Schinas G, Gogos C. Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Viruses. 2022 Nov 17;14(11):2540. doi: 10.3390/v14112540. |
| Label | URL |
|---|---|
| COVID-19 Drug Interactions | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000719967 | nirmatrelvir and ritonavir drug combination |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fact sheet for healthcare providers: Emergency use authorization for Paxlovid | View source |